At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
gabapentin 1200mg/day +2 moredrug
Likely dose
gabapentin 1200mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gabapentin Treatment of Cannabis Dependence
In Brief
A Phase 2 clinical trial evaluating gabapentin 1200mg/day, Placebo, and 1 other intervention for Cannabis Dependence and 2 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartNov 2009
Primary CompletionMay 2016
TodayJul 2026
First PostedSep 10, 2009
Enrollment StartNov 4, 2009
Primary CompletionMay 19, 2016
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 16.8 years ago
Interventions
gabapentin 1200mg/daydrug
gabapentin 1200mg/day for 12 weeks
Placebodrug
1200mg/day of placebo for 12 weeks
Manual-guided behavioral counselingbehavioral
Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.